1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
NAYA Biosciences, Inc.

NAYA Biosciences, Inc.

NAYA
NAYA Biosciences, Inc.US flagNASDAQ Global Market
2.20
USD
+0.17
- -
1.47MMarket Cap
NAYA Biosciences, Inc.
NAYA
(NASDAQ Global Market)

Recent

price

2.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
8.87
8.18
6.61
5.21
2.5
1.53
0.65
2.78
15.25
24.61
72.73
45.35
93.91
16.28
25.33
21.1
10.92
Revenue per Share
-654.06
-18.56
-73.72
-61.61
-70.32
-160.16
-277.84
-116.04
-37.94
-153.12
-106.5
-364.94
-150.22
-215.65
-67.37
-29.39
-41.25
Basic EPS, GAAP
-130.02
-38.22
-10.89
-3.99
-5.54
-1.79
-8.49
-18.55
-9.8
-33.47
61.7
-212.66
-146.38
-130.98
-43.6
-10.2
-10.61
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-946.13
-833.93
-711.06
-772.58
-842.73
-1,002.82
-885.48
-979.4
-1,006.75
-1,080.43
-1,173.7
-1,409.31
-877.85
-985.62
-484.8
-216.98
-140.59
Book Value per Share
-463.01
-307.09
-274.46
-315.3
-355.65
-405.44
-211.67
-253.29
-270.64
-136.19
-185.26
246.93
162.04
-19.35
-126.44
-191.47
-89.17
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
4
1
3
7
7
Sales/Revenue/Turnover
-2,915.54
-2,240.1
-983.35
-979.65
-2,236.39
-10,131.28
-5,090.89
-4,146.12
-226.98
-532.81
-120.8
-531.67
-125.39
-1,292.45
-224.04
-116.56
-138.48
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
Depreciation Expense
-5
- -
-1
-1
-1
-2
-5
-2
-1
-3
-2
-8
-7
-11
-8
-9
-25
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-7,375.28
-226.81
-1,115.3
-1,182.14
-2,810.77
-10,444.13
-42,426.61
-4,173.3
-248.87
-622.22
-146.43
-804.73
-159.97
-1,324.81
-266
-139.25
-377.72
Profit Margin (%)
-3
-3
-3
-3
-4
-4
-4
-5
-5
-3
- -
8
5
-3
-7
-17
-17
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
5
3
3
LT Debt
-3
-2
-3
-3
-4
-4
-4
-5
-5
-3
-4
6
7
-1
1
13
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
2
7
6
LT Borrowings
1
1
1
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
8
30
30
Shares Outstanding
- -
- -
1
Market Capitalization
2
3
1

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
2
1
2
Cash, Cash Equivalents & STI
- -
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
9
18
19
Payables & Accruals
5
8
10
ST Debt
2
7
6
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
80.42%
159.22%
1,328.13%
Free Cash Flow
23.04%
-102.53%
-39.26%
Net Income, GAAP
68.62%
63.1%
13.21%
Sales/Revenue/Turnover
160.94%
114.91%
116.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
1
1
3
2024
2
2
1
2
7
2025
2
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-49.17
-36.72
-8.43
- -
-67.37
2024
-7.55
-7.46
-5.04
-9.04
-29.39
2025
-12.53
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
BICO Group AB (publ) (BCCOY)
Perimeter Medical Imaging AI, Inc. (PYNKF)
Tenon Medical, Inc. (TNON)
Lumexa Imaging Holdings, Inc. Common Stock (LMRI)
FluroTech Ltd. (TEST.V)
aap Implantate AG (AAQ1.DE)
Business
NAYA Biosciences, Inc. NAYA Biosciences, Inc. (NASDAQ:NAYA) operates as a diversified life sciences company focused on advancing therapies in oncology, fertility, autoimmune diseases, and regenerative medicine. The company develops and commercializes a portfolio of clinical-stage assets, including NY-303, a GPC3 x NKp46 bifunctional antibody for hepatocellular carcinoma targeting non-responders to standard immunotherapy; NY-338, a CD38 x NKp46 bifunctional antibody for multiple myeloma and autoimmune diseases; NY-500, a PD-1 x VEGF bifunctional antibody for solid tumors; and NY-600, a PSMA x NKp46 bifunctional antibody for metastatic castration-resistant prostate cancer; alongside astatine-211 targeted alpha therapies through its NAYA Therapeutics subsidiary, gene therapy programs for rare mitochondrial diseases such as Leber’s Hereditary Optic Neuropathy acquired from Florida Biotechnologies, and fertility solutions via INVOcell devices and clinic operations. NAYA Biosciences maintains headquarters in Sarasota, Florida, with additional facilities in Miami and Aventura, and conducts operations primarily in the United States while pursuing global partnerships, including recent clinical development collaborations in China. Founded in 2023 through the merger of Clinigence Holdings and 4Front Biotech, the company completed a transformative all-stock merger with INVO Bioscience in October 2024, enabling public trading under the NAYA ticker, enhanced capital access, and integration of fertility clinics with oncology assets; subsequent developments include a strategic decision in April 2025 to separate fertility and oncology businesses, expansion of its oncology pipeline with new PD-1 combinations and NK-cell engagers cleared for Phase 1/2 trials in 2025, partnerships with Alpha Nuclide for China development and Atley Solutions for radiopharmaceutical acceleration, and board nominations to support growth.

Company News

APIChat

  • globenewswire.com

    INVO Fertility Confirms New Nasdaq Trading Symbol of “IVF”

  • globenewswire.com

    NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”

  • globenewswire.com

    NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

  • globenewswire.com

    NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment

  • globenewswire.com

    NAYA Biosciences Announces Nomination of New Board Members

  • globenewswire.com

    INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)